Literature DB >> 30216633

Vascular compliance in women with polycystic ovary syndrome treated with spironolactone.

Ozgul Muneyyirci-Delale1,2, Sherilyne Co3, Nathaniel Winer4.   

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age in the United States and has been associated with several diseases including cardiovascular disease, obesity, and glucose intolerance. In this study, systolic blood pressure, diastolic blood pressure, pulse pressure (vascular compliance), large artery elasticity, systemic vascular resistance (SVR), total vascular impedance (TVI), and body mass index (BMI) were measured before and after treatment with spironolactone in 10 women with PCOS. Systolic BP, diastolic BP, and BMI were similar prior to treatment and after treatment. Pulse pressure decreased slightly post-treatment compared to pretreatment but not to significance (P = 0.07). The results show that after treatment with spironolactone, there was a statistically significant increase in large artery elasticity (P = 0.047), while there was a statistically significant decrease in SVR and TVI (P = 0.0005 and P = 0.03). This study indicates that treatment with spironolactone improves large artery elasticity and reduces systemic vascular resistance without any change in small artery elasticity. ©2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  PCOS; cardiovascular; compliance; spironolactone; vascular

Mesh:

Substances:

Year:  2018        PMID: 30216633      PMCID: PMC8031109          DOI: 10.1111/jch.13385

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  43 in total

1.  Effects of estrogen therapy on arterial resistance and pulsatility in postmenopausal women.

Authors:  A Federici; M Ciccone; E Cicinelli; M Lombardi; M V Pitzalis; P Galantino; V Pinto
Journal:  Angiology       Date:  2001-01       Impact factor: 3.619

2.  Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.

Authors:  F Zannad; F Alla; B Dousset; A Perez; B Pitt
Journal:  Circulation       Date:  2000-11-28       Impact factor: 29.690

Review 3.  Aldosterone receptor antagonists--how cardiovascular actions may explain their beneficial effects in heart failure.

Authors:  P Ovaert; J Elliott; F Bernay; E Guillot; T Bardon
Journal:  J Vet Pharmacol Ther       Date:  2010-04       Impact factor: 1.786

4.  Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study.

Authors:  Sarah Wild; Tracey Pierpoint; Howard Jacobs; Paul McKeigue
Journal:  Hum Fertil (Camb)       Date:  2000       Impact factor: 2.767

5.  Polycystic ovary morphology: age-based ultrasound criteria.

Authors:  Hyun-Jun Kim; Judith M Adams; Jens A Gudmundsson; Gudmundur Arason; Cindy T Pau; Corrine K Welt
Journal:  Fertil Steril       Date:  2017-08-12       Impact factor: 7.329

Review 6.  CLINICAL PRACTICE. Polycystic Ovary Syndrome.

Authors:  Christopher R McCartney; John C Marshall
Journal:  N Engl J Med       Date:  2016-07-07       Impact factor: 91.245

7.  Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome.

Authors:  D Cibula; R Cífková; M Fanta; R Poledne; J Zivny; J Skibová
Journal:  Hum Reprod       Date:  2000-04       Impact factor: 6.918

8.  Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension.

Authors:  J Blacher; G Amah; X Girerd; A Kheder; H Ben Mais; G M London; M E Safar
Journal:  Am J Hypertens       Date:  1997-12       Impact factor: 2.689

9.  Obesity, rather than menstrual cycle pattern or follicle cohort size, determines hyperinsulinaemia, dyslipidaemia and hypertension in ageing women with polycystic ovary syndrome.

Authors:  M W Elting; T J Korsen; J Schoemaker
Journal:  Clin Endocrinol (Oxf)       Date:  2001-12       Impact factor: 3.478

Review 10.  Effects of antihypertensive drugs on arterial stiffness.

Authors:  Tanja Dudenbostel; Stephen P Glasser
Journal:  Cardiol Rev       Date:  2012 Sep-Oct       Impact factor: 2.644

View more
  1 in total

1.  Vascular compliance in women with polycystic ovary syndrome treated with spironolactone.

Authors:  Ozgul Muneyyirci-Delale; Sherilyne Co; Nathaniel Winer
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-09-14       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.